Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) EBT Margin: 2016-2025

Historic EBT Margin for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to 10,995.98%.

  • Rocket Pharmaceuticals' EBT Margin fell 356198.00% to 10,995.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 13,126.60%, marking a year-over-year decrease of 111711.00%. This contributed to the annual value of 14,147.61% for FY2024, which is 48116.00% up from last year.
  • Rocket Pharmaceuticals' EBT Margin amounted to 10,995.98% in Q3 2025, which was down 26.89% from 15,039.96% recorded in Q2 2025.
  • Rocket Pharmaceuticals' EBT Margin's 5-year high stood at 15,263.06% during Q2 2024, with a 5-year trough of 2,315.79% in Q1 2021.
  • Moreover, its 3-year median value for EBT Margin was 13,684.01% (2023), whereas its average is 13,705.15%.
  • In the last 5 years, Rocket Pharmaceuticals' EBT Margin skyrocketed by 1,207,027bps in 2021 and then tumbled by 356,198bps in 2025.
  • Over the past 5 years, Rocket Pharmaceuticals' EBT Margin (Quarterly) stood at 9,491.58% in 2021, then surged by 513,455bps to 14,626.12% in 2022, then slumped by 123,570bps to 13,390.43% in 2023, then tumbled by 37,774bps to 13,012.68% in 2024, then plummeted by 356,198bps to 10,995.98% in 2025.
  • Its last three reported values are 10,995.98% in Q3 2025, 15,039.96% for Q2 2025, and 13,458.47% during Q1 2025.